FENSOME ANDREW

Disclosed herein are oxazolidone compounds of the given formula wherein the substituents are as defined within the specification. Said compounds are useful for treating hormone-related conditions including contraception, treating or prevent…

In one embodiment, compounds of the following structure are described, wherein R1 to R7 are described herein. Also provided are methods for preparing these compounds and methods of contraception treating or preventing fibroids treating or p…

Compounds of the following structure are provided, wherein n, R1-R3 and R6-R9 are defined below, as are methods of preparing and using these compounds for contraception treating or preventing fibroids, uterine leiomyomata, endometriosis, dy…

In one embodiment, compounds of the following structure are described, wherein R1 to R7 are described herein. Formula (I). Also provided are methods for preparing these compounds and methods of contraception treating or preventing fibroids …

The present invention provides methods of inducing contraception which includes delivering to a female a composition containing a compound of formula I, or tautomers thereof, in a regimen which involves delivering one or more of a selective…

The present invention provides methods of inducing contraception which includes delivering to a female a composition containing a compound of formula I, or tautomers thereof, in a regimen which involves delivering one or more of a selective…

Compounds of the following structure are described: wherein R1-R6, m, V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety o…

Compounds of the following structure are described: wherein R1, R2, R5, R6, V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a var…

Compounds of the structure (I) are described, wherein R1, R2, R5, R6, V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety o…

Compounds of the structure (I) are described, wherein R 1 , R 2 , R 5 , R 6 , V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a v…

Compounds of formula (I), or pharmaceutically acceptable salts thereof, are provided, wherein R1-R6 and X are defined herein. Also provided are methods of preparing the compounds of formula (I), pharmaceutical compositions and kits containi…

Compounds of the following structure are provided, wherein R1-R4 and R6-R9 are defined below, as are methods of preparing and using these compounds for contraception treating or preventing fibroids, uterine leiomyomata, endometriosis, dysfu…

Compounds of the following structure are described: wherein R1-R6, R16, m, V, W, X, Y, and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a var…

In one embodiment, compounds of the following structure are described, wh erein R1 to R7 are described herein. Formula (I). Also provided are methods for preparing these compounds and methods of contraception treating or prev enting fibroid…

In one embodiment, compounds of the following structure are described, wherein R1 to R7 are described herein. Formula (I): Also provided are methods for preparing these compounds and methods of contraception; treating or preventing fibroids…

In one embodiment, compounds of the following structure are described, wherein R1 to R7 are described herein. Also provided are methods for preparing these compounds and methods of contraception; treating or preventing fibroids; treating or…

Compounds of the following structure are described: wherein R1-R6, R10, m, V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a vari…

Compounds of structure (I) are described, wherein R1-R6, R10, m, V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer thereof. These compounds are useful for treating a variety of hormone-related conditions…

Compounds of the following structure are described: wherein R1-R6, m, V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety o…

Compounds of the following structure are described (I), wherein R1-R6, m, V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a varie…

Compounds of the following structure are described: wherein R1-R6, m, V, W, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variet…

Compounds of the following structure are described: wherein R1, R2, R5, R, V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a vari…

Compounds of the structure (I) are described, wherein R1, R2, R5, R6, V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, t automer, metabolite or prodrug thereof. These compounds are useful for treat ing a variety…

Compounds of the structure (I) are described, wherein R1, R2, R5, R6, V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety o…

Compounds of the following structure are described: wherein R1-R6, R11, R12, m, V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a…